Asia-Pacific In-Vitro Diagnostics Market : Global Industry Analysis, Size, Share, Growth, Trends, and Forecast

SDKI Inc. published a new research report on the Asia Pacific In Vitro Diagnostic Market-Growth, Trends, Impact of COVID-19, and Forecasts 2022-2030. The report provides a complete assessment of the market and its growth prospects, along with new business opportunities in the industry. It also includes market size and annual growth during the 2022-2030 forecast period.

Report sample URL
https://www.sdki.jp/sample-request-114035

The Asia Pacific in vitro diagnostic market held a value of US $ 17,812.62 million in 2020. From a market value of US $ 18,824.38 million in 2022, it is estimated to reach US $ 27,712.16 million by 2030 and is expected to grow at a CAGR of 5.68% during the forecast period.

In vitro diagnosis (IVD) is always essential for the detection of infections. Recently, many molecular and immunoassays have been performed to detect COVID-19. However, in current scenarios, high quality diagnostics that provide faster and more accurate test results are essential. The COVID-19 pandemic spotlighted the in vitro diagnostic industry in the Asian region with rapid diagnostic development, rapid regulatory approval, and enhanced distribution in various regions to help control the spread of the virus. .. In addition, the prevalence of various chronic diseases has increased significantly in the Asia-Pacific countries over the last decade. The threat to public health from these diseases has increased significantly, resulting in the growing adoption of new diagnostic techniques, including point-of-care tests. These factors are expected to contribute to the growth of this market.

Market segment

The Asia-Pacific in vitro diagnostic market is by test type (clinical chemistry, molecular diagnostics, immunodiagnosis, hematology, and others), product (equipment, reagents, and others), gender (disposable IVD equipment and reusable). IVD device), by application (infection, diabetes, cancer / oncology, cardiology, autoimmune disease, nephrology, and others), by end-user (diagnostic laboratory, hospital / clinic, and others), and region It will be split separately. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.

Based on the test type, the clinical chemistry segment is expected to grow the highest during the forecast period. Clinical chemistry is a combination of analytics, measurement, information technology, and workflow management. Technological advances are driving the automation of detection techniques for biologically important ions (salts and minerals), small organic molecules, and large molecules such as enzymes, transport proteins, and lipoproteins. This is expected to contribute to the growth of this segment. An analyzer is a device that analyzes samples such as blood, serum, and urine. Clinical chemistry analyzers are growing at a high rate due to the developed technology used in these instruments.

Area overview

The Asia-Pacific region is a region of middle class population growth, stable economy, urban population growth, and government support. The country is undergoing major changes in the private health sector, which is driving the growth of the in vitro diagnostic (IVD) market. In Asia-Pacific countries such as India, Japan and China, the demand for IVD devices is increasing due to the aging population, the prevalence of lifestyle-related diseases and the growth of the medical sector. In addition, the market is affected by the establishment of independent centers, independent diagnostic chains, and academic institutions. In addition, many governments have taken some initiatives regarding in-vitro diagnostics. This is also driving the growth of the entire market. The Government of India is taking proactive steps to enhance the capacity of the IVD sector in the country. The development of the Medical Device Regulations (2017), which came into force on January 1, 2018, was an important means of driving investment inflows into this sector and reducing device manufacturing costs.

Key Players in the Market

Key players in the Asia Pacific in vitro diagnostic market include Abbott Laboratories, Siemens Healthineers AG, Thermo Fisher Scientific, and F. Hoffmann-La Roche Ltd. The study includes in-depth competitive analysis, corporate profiles, recent developments, and key market strategies for these key companies in the Asia Pacific in vitro diagnostic market.

Detailed contents of the survey report
https://www.sdki.jp/reports/asia-pacific-in-vitro-diagnostics-market/114035

Contact Us

Hina Miyazu
15/F Cerulean Tower, 26-1 Sakuragaoka-cho
Tokyo, Shibuya-ku, Japan
+ 81345720790
sales@sdki.jp

SDKI Inc. Company Profile

SDKI Inc.'s goal is market scenarios in various countries such as Japan, China, the United States, Canada, the United Kingdom, and Germany. Is to clarify. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.

This release was published on openPR.